Tafinlar Alternatives Compared
| Tafinlar (dabrafenib) | Opdivo (nivolumab) | Enhertu (fam-trastuzumab deruxtecan) |
|
|---|
| Tafinlar (dabrafenib) | Opdivo (nivolumab) | Enhertu (fam-trastuzumab deruxtecan) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Melanoma - Metastatic, Non Small Cell Lung Cancer, Thyroid Cancer, Low-Grade Glioma, Solid Tumors. Tafinlar may also be used for purposes not listed in this medication guide. |
Prescription only
Opdivo is an immune checkpoint inhibitor that may be used to treat many different cancers including melanoma, bladder cancer, liver cancer, colorectal cancer, and lung cancer. Fatigue, skin... View more |
Prescription only
Prescribed for Breast Cancer - Metastatic, Solid Tumors, Non Small Cell Lung Cancer, Breast Cancer, Gastric Cancer. Enhertu may also be used for purposes not listed in this medication guide. |
Related suggestions Popular comparisons
|
|||||||||||||||||||||||
| More about Tafinlar (dabrafenib) | More about Opdivo (nivolumab) | More about Enhertu (fam-trastuzumab deruxtecan) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Tafinlar has an average rating of 7.5 out of 10 from a total of 2 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 0% reported a negative effect. |
Opdivo has an average rating of 5.8 out of 10 from a total of 95 ratings on Drugs.com. 53% of reviewers reported a positive effect, while 40% reported a negative effect. |
Enhertu has an average rating of 8.1 out of 10 from a total of 34 ratings on Drugs.com. 74% of reviewers reported a positive effect, while 3% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Tafinlar side effects |
View all Opdivo side effects |
View all Enhertu side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Tafinlar prices |
View all Opdivo prices |
View all Enhertu prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
22 hours |
640.8 hours |
136.8 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 509 drugs are known to interact with Tafinlar:
|
A total of 594 drugs are known to interact with Opdivo:
|
A total of 179 drugs are known to interact with Enhertu:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
May 29, 2013 |
December 22, 2014 |
N/A |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Rybrevant
Rybrevant is used to treat advanced non-small cell lung cancer (NSCLC) in adults that has certain ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Mekinist
Mekinist is used to treat melanoma, non-small cell lung cancer, thyroid cancer, solid tumors, and ...
Yervoy
Yervoy (ipilimumab) is a cancer treatment used for lung cancer, melanoma, renal cell carcinoma ...
Mektovi
Mektovi (binimetinib) is an oral kinase inhibitor that may be used in combination with encorafenib ...
Braftovi
Braftovi is a targeted cancer treatment used in combination with Mektovi, mFOLFOX6, or Erbitux, to ...
Ipilimumab
ipilimumab (Yervoy) is an immunotherapy used for melanoma, renal cell carcinoma, non-small cell ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.